Barr Laboratories, Inc., has received final approval from the FDA for its application to manufacture and market drug clonazepam orally disintegrating tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2 mg, the generic equivalent of Hoffman La Roche’s Klonopin generic Wafers. Klonopin® can be used alone or as an adjunct in patients with seizures and panic disorder, with or without agoraphobia.
